December 16: The Week in Cancer News
A second KRAS inhibitor is approved for lung cancer, and a BTK inhibitor challenges standard of care for relapsed or refractory CLL.
Thanks to Lifesaving Cancer Research18,000,000cancer survivors in the United States are living with, through, and beyond their disease.
Your donation to the American Association for Cancer Research helps our more than 58,000 members worldwide drive progress against cancer.
Donate Now